泰利福 Rüsch™ EZ-Blocker™一次性使用双侧支气管堵塞器获 NMPA 批准，为中国单肺通气手术带来新选择

发布时间：2025-08-11 17:41

泰利福公司（NYSE:TFX），全球领先的医疗技术公司，今日宣布其旗下Rüsch™EZ-Blocker™一次性使用双侧支气管堵塞器已成功通过中国国家药品监督管理局（NMPA）的严格审评审批，并正式取得医疗器械注册证（注册证编号：国械注进20252080316）。这不仅是泰利福中国产品组合的一次重要升级优化，更为公司在华业务的增长注入强劲动力。

泰利福Rüsch™EZ-Blocker™一次性使用双侧支气管堵塞器

泰利福中国始终致力于为全球医疗市场提供创新的医疗解决方案，此次Rüsch™EZ-Blocker™一次性使用双侧支气管堵塞器在华获批，是泰利福深耕中国市场、满足中国患者医疗需求的又一重要举措。未来，泰利福将继续优化其在中国的产品组合，为推动中国医疗健康事业的发展贡献更多力量。

AboutTeleflexIncorporated

Asa globalproviderofmedicaltechnologies,Teleflexisdrivenbyourpurposetoimprovethehealthandqualityofpeople'slives.Throughourvisiontobecomethemosttrustedpartnerintheworldofhealthcare,weoffera diverseportfoliowithsolutionsinthetherapyareasofanesthesia,emergencymedicine,interventionalcardiologyandradiology,surgical,vascularaccess,andurology.Webelievethatthepotentialofgreatpeople,purposedriveninnovation,andworld-classproductscanshapethefuturedirectionofhealthcare.

TeleflexisthehomeofArrow™,Barrigel™,Deknatel™,LMA™,Pilling™,QuikClot™,Rüsch™,UroLift™andWeck™–trustedbrandsunitedbya commonsenseofpurpose.

AtTeleflex,weareempoweringthefutureofhealthcare.

Forward-LookingStatements

Anystatementscontainedinthispressreleasethatdonotdescribehistoricalfactsmayconstituteforward-lookingstatements.Anyforward-lookingstatementscontainedhereinarebasedonourmanagement'scurrentbeliefsandexpectations,butaresubjecttoa numberofrisks,uncertaintiesandchangesincircumstances,whichmaycauseactualresultsorcompanyactionstodiffermateriallyfromwhatisexpressedorimpliedbythesestatements.TheserisksanduncertaintiesareidentifiedanddescribedinmoredetailinourfilingswiththeSecuritiesandExchangeCommission,includingourAnnualReportonForm10-K.

Teleflex,theTeleflexlogoaretrademarksorregisteredtrademarksofTeleflexIncorporatedoritsaffiliates,intheU.S.and/orothercountries.

Contacts:

Teleflex

LawrenceKeusch

VicePresident,InvestorRelationsandStrategyDevelopment

TeleflexChina

Yolanda Li(李婪)

MarketingCommunicationsSupervisor(市场传播主管),China